Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pentosan Polysulfate Sodium

            Therapeutic Area: Musculoskeletal

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bell Potter Securities

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 20, 2020

            Details:

            Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.